{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:49:47Z","timestamp":1767134987743,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd009070","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000}}],"reference-count":142,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009070.pub2","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T11:22:47Z","timestamp":1536232967000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients"],"prefix":"10.1002","volume":"2018","author":[{"given":"Jes\u00fas","family":"L\u00f3pez-Alcalde","sequence":"first","affiliation":[{"name":"Universidad Francisco de Vitoria (UFV) Madrid; Faculty of Medicine; Ctra. Pozuelo-Majadahonda km. 1,800 Madrid Spain"},{"name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS); Clinical Biostatistics Unit; Ctra. Colmenar, km. 9.100 Madrid Spain 28034"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Rodriguez-Barrientos","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial de Atenci\u00f3n Primaria, Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC); Unidad de apoyo a la Investigaci\u00f3n; J\u00e1tiva N\u00ba23 2\u00bac Madrid Spain 28007"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Redondo-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial Atenci\u00f3n Primaria; Centro de Salud Ramon y Cajal; Jaboner\u00eda 67 Madrid Spain 28921"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Mu\u00f1oz-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial Atenci\u00f3n Primaria; Centro de Salud Buenos Aires; Pio Felipe Madrid Spain 28038"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Molero Garc\u00eda","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial Atenci\u00f3n Primaria; Centro de Salud San Andr\u00e9s; Alberto Palacios, n\u00ba 22 Madrid Madrid Spain 28021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial Atenci\u00f3n Primaria; Centro de Salud San Crist\u00f3bal; Benimamet 24 Madrid Spain 28021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Heras-Mosteiro","sequence":"additional","affiliation":[{"name":"Rey Juan Carlos University; Department of Preventive Medicine and Public Health & Immunology and Microbiology; Avda. Atenas s\/n Alcorc\u00f3n Madrid Spain 28922"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Marin-Ca\u00f1ada","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial Atencion Primaria de Madrid; Centro de Salud Villarejo de Salvanes; Calle Hospital 7 Villarejo de Salvanes Madrid Spain 28590"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Casanova-Colominas","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial de Atenci\u00f3n Primaria; Centro de Salud Ciudad de los Periodistas; Valencia de don Juan 10 28034 Madrid Madrid Spain 28034"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaya","family":"Azcoaga-Lorenzo","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial Atenci\u00f3n Primaria; Centro de Salud Los Pintores; C\/Prolongaci\u00f3n Cordoba s\/n Parla Madrid Spain 29981"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Hernandez Santiago","sequence":"additional","affiliation":[{"name":"University of St Andrews; Division of Population and Behavioural Sciences, School of Medicine; North Haugh Dundee UK KY16 9TF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"G\u00f3mez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial Atenci\u00f3n Primaria; Centro de Salud Mirasierra; C\/ Mirador de la Reina n\u00ba 117 Madrid Spain 28035"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"10.1002\/14651858.CD009070.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pupt.2017.06.008","article-title":"Individualizing duration of antibiotic therapy in community-acquired pneumonia","volume":"45","author":"Aliberti","year":"2017","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"16","key":"10.1002\/14651858.CD009070.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/ajhp\/57.16.1506","article-title":"Changing physician prescribing behavior: the community-acquired pneumonia intervention trial","volume":"57","author":"Coley","year":"2000","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF03256648","article-title":"Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections","volume":"2","author":"Darkes","year":"2003","journal-title":"American Journal of Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1179\/joc.2004.16.1.82","article-title":"Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia","volume":"16","author":"Demartini","year":"2004","journal-title":"Journal of Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0149-2918(97)80047-1","article-title":"Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study","volume":"19","author":"Donowitz","year":"1997","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"7554","key":"10.1002\/14651858.CD009070.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"Moussaoui","year":"2006","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD009070.pub2-BIB0009|cit9","first-page":"1","article-title":"Stopping antibiotics after 5 days in clinically stable community-acquired pneumonia was noninferior to usual care","volume":"165","author":"Fekete","year":"2016","journal-title":"ACP Journal Club"},{"issue":"9","key":"10.1002\/14651858.CD009070.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1185\/030079904X2556","article-title":"Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia","volume":"20","author":"File","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijantimicag.2004.10.007","article-title":"Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin\/clavulanate (2000\/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains","volume":"25","author":"File","year":"2005","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jac\/dkm119","article-title":"Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study","volume":"60","author":"File","year":"2007","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jac\/dkm333","article-title":"Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study - authors' response","volume":"60","author":"File","year":"2007","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Hammerschlag MR Comment on: Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study Journal of Antimicrobial Chemotherapy 2007 902-3; author reply","DOI":"10.1093\/jac\/dkm290"},{"issue":"3","key":"10.1002\/14651858.CD009070.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0149-2918(01)80047-3","article-title":"Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials","volume":"23","author":"Fogarty","year":"2001","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/rmed.2003.1492","article-title":"Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis","volume":"97","author":"Hagberg","year":"2003","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkg154","article-title":"Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae","volume":"51","author":"Hammerschlag","year":"2003","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/jac\/dkm290","article-title":"Comment on: Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study","volume":"60","author":"Hammerschlag","year":"2007","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD009070.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/13543784.17.3.387","article-title":"Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections","volume":"17","author":"Hammerschlag","year":"2008","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"10","key":"10.1002\/14651858.CD009070.pub2-BIB0020|cit20","first-page":"E206","article-title":"Impact of antibiotic choice on pneumonia readmission rates","volume":"34","author":"Hemenway","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1002\/14651858.CD009070.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1185\/030079906X132505","article-title":"Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections","volume":"22","author":"Khashab","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0022|cit22","first-page":"137","article-title":"Intravenous azithromycin - single dose 1.5 g vs. 500 mg once daily for 3 days in patients with community-acquired pneumonia: a prospective and randomised study","volume":"18","author":"Lagler","year":"2012","journal-title":"Clinical Microbiology and Infection"},{"issue":"9","key":"10.1002\/14651858.CD009070.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.amjmed.2007.04.023","article-title":"Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis","volume":"120","author":"Li","year":"2007","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1742-1241.2003.tb10543.x","article-title":"Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections","volume":"57","author":"Lorenz","year":"2003","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejim.2017.06.012","article-title":"Time to antibiotics administration and outcome in community-acquired pneumonia: secondary analysis of a randomized controlled trial","volume":"43","author":"Marti","year":"2017","journal-title":"European Journal of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009070.pub2-BIB0026|cit26","first-page":"304","article-title":"Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease","volume":"11","author":"McCabe","year":"1989","journal-title":"Clinical Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD009070.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1185\/030079904125003944","article-title":"Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials","volume":"20","author":"Niederman","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1185\/030079904125003601","article-title":"Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin","volume":"20","author":"Niederman","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"78a","DOI":"10.1378\/chest.2277759","article-title":"Results from a phase 3 trial in moderate to moderately severe community acquired bacterial pneumonia (CABP) treated as outpatients with a new oral macrolide, solithromycin","volume":"148","author":"Oldach","year":"2015","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1542\/peds.2013-1773","article-title":"Comparative effectiveness of empiric antibiotics for community-acquired pneumonia","volume":"133","author":"Queen","year":"2014","journal-title":"Pediatrics"},{"issue":"12","key":"10.1002\/14651858.CD009070.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1007\/s00108-015-3839-0","article-title":"Community-acquired pneumonia. New treatment concepts","volume":"56","author":"Rasche","year":"2015","journal-title":"Internist"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000029424","article-title":"Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime","volume":"66","author":"Rovira","year":"1999","journal-title":"Respiration; International Review of Thoracic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD009070.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02561528","article-title":"Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study","volume":"27","author":"Schonwald","year":"1999","journal-title":"Infection"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0149-2918(05)80214-0","article-title":"A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or = 65 years with community-acquired pneumonia","volume":"27","author":"Shorr","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD009070.pub2-BIB0035|cit35","first-page":"1895-6; author","article-title":"Comments on: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days","volume":"20","author":"Cifaldi","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1185\/030079904125003610","article-title":"Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days","volume":"20","author":"Tellier","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0037|cit37","first-page":"1331","article-title":"Corrections to: Tellier G, Chang JR, Carl V. Comparison of hospitalization rates in patients with community acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days","volume":"20","author":"Tellier","year":"2004","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0038|cit38","unstructured":"Tellier G Isakov T Petermann W Patel M Lavin B Efficacy and safety of telithromycin for 5 or 7 days vs clarithromycin for 10 days in the treatment of patients with community acquired pneumonia Abstracts - 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy: ASM's annual meeting on infectious diseases; 2002 September 27 - 30; San Diego, California, USA Washington DC American Society for Microbiology 2002 L373"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1378\/chest.112.2.406","article-title":"Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia","volume":"112","author":"Brande","year":"1997","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000086576","article-title":"Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and\/or erythromycin","volume":"51","author":"Rensburg","year":"2005","journal-title":"Chemotherapy"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009070.pub2-BIB0042|cit42","first-page":"128","article-title":"A multicentre randomized study of levofloxacin 750mg IV short-course versus 500mg IV\/PO sequential convention-course for the treatment of community-acquired pneumonia in mainland China","volume":"20","author":"Zhao","year":"2015","journal-title":"Respirology"},{"issue":"9","key":"10.1002\/14651858.CD009070.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.21037\/jtd.2016.08.30","article-title":"A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion\/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia","volume":"8","author":"Zhao","year":"2016","journal-title":"Journal of Thoracic Disease"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0044|cit44","unstructured":"NCT02903836 Phase II study of oral nafithromycin in CABP clinicaltrials.gov\/ct2\/show\/NCT02903836"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jhm.382","article-title":"Blood cultures for community-acquired pneumonia: are they worthy of two quality measures: a systematic review","volume":"4","author":"Afshar","year":"2009","journal-title":"Journal of Hospital Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1378\/chest.110.2.343","article-title":"Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators","volume":"110","author":"Albaum","year":"1996","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1183\/09031936.00130909","article-title":"Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia","volume":"36","author":"Aliberti","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"7454","key":"10.1002\/14651858.CD009070.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1473-3099(03)00721-7","article-title":"Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers","volume":"3","author":"Barlow","year":"2003","journal-title":"Lancet Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0050|cit50","first-page":"177","article-title":"Duration of treatment and oral administration of antibiotics in community acquired pneumonia","volume":"33","author":"Bernal-Vargas","year":"2016","journal-title":"Revista Chilena de Infectologia"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1542\/peds.2013-3729","article-title":"Treatment of mycoplasma pneumonia: a systematic review","volume":"133","author":"Biondi","year":"2014","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009070.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1378\/chest.129.1_suppl.95S","article-title":"Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines","volume":"129","author":"Braman","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0053|cit53","unstructured":"Brinker A Telithromycin-associated hepatotoxicity Presentation to the Joint meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Committee, US Food and Drug Administration; 2006 December 14-15; Silver Spring (MD) 2006"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0054|cit54","first-page":"494-503","article-title":"The rate and economic burden of community-acquired pneumonia in a working-age population","volume":"6","author":"Broulette","year":"2013","journal-title":"American Health Drug Benefits"},{"issue":"7572","key":"10.1002\/14651858.CD009070.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0056|cit56","unstructured":"Cochrane Consumers and Communication Group Study design guide for review authors, 2013 https:\/\/figshare.com\/articles\/Study_design_guide\/6818900"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jinf.2016.04.008","article-title":"Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia","volume":"73","author":"Chalmers","year":"2016","journal-title":"Journal of Infection"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1183\/09031936.00168811","article-title":"Community-acquired pneumonia in outpatients: aetiology and outcomes","volume":"40","author":"Cill\u00f3niz","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0059|cit59","unstructured":"COMET Initiative Database www.comet-initiative.org\/resources 2010"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0060|cit60","unstructured":"Cordero PM Ruiz-Aragon J Linde JMM Marquez-Pelaez S Sanchez VM Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections. Systematic review of literature Revista Chilena de Infectolog\u00eda 2013 591 7"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"c2096","DOI":"10.1136\/bmj.c2096","article-title":"Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis","volume":"340","author":"Costelloe","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0062|cit62","unstructured":"Veritas Health Innovation Covidence 2017"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0063|cit63","volume-title":"Systematic Reviews. CRD's Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/fampra\/cmx037","article-title":"Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews","volume":"34","author":"Dawson-Hahn","year":"2017","journal-title":"Family Practice"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0065|cit65","unstructured":"Deeks JJ Higgins JP Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"13","key":"10.1002\/14651858.CD009070.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2165\/00003495-200868130-00004","article-title":"Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis","volume":"68","author":"Dimopoulos","year":"2008","journal-title":"Drugs"},{"issue":"7","key":"10.1002\/14651858.CD009070.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.revmed.2015.12.003","article-title":"Short-course antibiotic regimens: up-to-date","volume":"37","author":"Dinh","year":"2016","journal-title":"La Revue de Medecine Interne"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2165\/00002018-200730080-00006","article-title":"Telithromycin use and spontaneous reports of hepatotoxicity","volume":"30","author":"Dore","year":"2007","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0069|cit69","unstructured":"Doull M Runnels V Tudiver S Boscoe M Sex and gender in systematic reviews: planning tool methods.cochrane.org\/sites\/methods.cochrane.org.equity\/files\/public\/uploads\/SRTool_PlanningVersionSHORTFINAL.pdf 2011"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"g67","DOI":"10.1136\/bmj.g6722","article-title":"Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance","volume":"349","author":"Eccles","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0071|cit71","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA) Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections, 2004 ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003417.pdf 2004"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0072|cit72","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA) Withdrawal assessment report for FACTIVE (International Nonproprietary Name: Gemifloxacin) Procedure No. EMEA\/H\/C\/995 www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/2010\/01\/WC500060988.pdf 2009"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0073|cit73","unstructured":"Campbell & Cochrane Equity Methods Group Equity checklist for systematic review authors methods.cochrane.org\/sites\/methods.cochrane.org.equity\/files\/public\/uploads\/EquityChecklist2012.pdf 2012"},{"issue":"9400","key":"10.1002\/14651858.CD009070.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0140-6736(03)15021-0","article-title":"Community-acquired pneumonia","volume":"362","author":"File","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"993-1016, xi","DOI":"10.1016\/j.idc.2004.07.011","article-title":"Antimicrobial therapy of community-acquired pneumonia","volume":"18","author":"File","year":"2004","journal-title":"Infectious Disease Clinics of North America"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009070.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/421354","article-title":"Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia","volume":"39","author":"File","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jclinepi.2004.09.013","article-title":"Uncertainty method improved on best-worst case analysis in a binary meta-analysis","volume":"58","author":"Gamble","year":"2005","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9611","key":"10.1002\/14651858.CD009070.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(08)60216-0","article-title":"Community-acquired pneumonia","volume":"371","author":"Garau","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0079|cit79","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005976.pub2","article-title":"Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months","author":"Haider","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD009070.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/archinte.162.11.1278","article-title":"Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia","volume":"162","author":"Halm","year":"2002","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005532.pub3","article-title":"Vitamin C for preventing and treating pneumonia","author":"Hemil\u00e4","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD009070.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0084|cit84","unstructured":"Higgins JP Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0085|cit85","unstructured":"Higgins JP Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0086|cit86","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0087|cit87","first-page":"g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e0148741","DOI":"10.1371\/journal.pone.0148741","article-title":"Risk factors for long-term mortality after hospitalization for community-acquired pneumonia: a 5-year prospective follow-up study","volume":"11","author":"Holter","year":"2016","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1002\/14651858.CD009070.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0011-393X(95)85095-3","article-title":"Five-day azithromycin in the treatment of patients with community-acquired pneumonia","volume":"56","author":"Hopkins","year":"1995","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.crad.2004.01.011","article-title":"Inter-observer variation in the interpretation of chest radiographs for pneumonia in community-acquired lower respiratory tract infections","volume":"59","author":"Hopstaken","year":"2004","journal-title":"Clinical Radiology"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.arbr.2012.12.003","article-title":"Improved management of community-acquired pneumonia in the emergency department","volume":"49","author":"Juli\u00e1n-Jim\u00e9nez","year":"2013","journal-title":"Archivos de Bronconeumologia"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009070.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1086\/421352","article-title":"Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update","volume":"39","author":"Karchmer","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD009070.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jac\/dkf046","article-title":"Patient compliance with antibiotic treatment for respiratory tract infections","volume":"49","author":"Kardas","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00151829-200504040-00002","article-title":"Short-course antimicrobial therapy for community-acquired pneumonia","volume":"4","author":"Kolditz","year":"2005","journal-title":"Treatments in Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009070.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1378\/chest.122.3.920","article-title":"The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia","volume":"122","author":"Lamping","year":"2002","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD009070.pub2-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008032.pub3","article-title":"Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months","author":"Lassi","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0098|cit98","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009070.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"issue":"9859","key":"10.1002\/14651858.CD009070.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0101|cit101","unstructured":"Lim WS Smith D Wise M Welham S 2015 - Annotated BTS Guideline for the management of CAP in adults (2009) - Summary of recommendations www.brit-thoracic.org.uk\/document-library\/clinical-information\/pneumonia\/adult-pneumonia\/annotated-bts-cap-guideline-summary-of-recommendations\/ 2015"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0102|cit102","unstructured":"Loke YK Price D Herxheimer A Chapter 14: Adverse effects. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group","volume":"31","author":"Mandell","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Mandell LA File TM Jr Short-course treatment of community-acquired pneumonia Clinical Infectious Diseases 2003 761 3","DOI":"10.1086\/377567"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009070.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Marras TK Nopmaneejumruslers C Chan CK Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis American Journal of Medicine 2004 385 93","DOI":"10.1016\/j.amjmed.2003.11.013"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0107|cit107","unstructured":"US National Library of Medicine MeSH Browser 2018 www.ncbi.nlm.nih.gov\/mesh\/"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Migliori GB Langendam MW D'Ambrosio L Centis R Blasi F Huitric E Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones European Respiratory Journal 2012 814 22","DOI":"10.1183\/09031936.00036812"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD009070.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archinte.162.9.1059","article-title":"Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study","volume":"162","author":"Mortensen","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0111|cit111","unstructured":"National Institute for Health and Care Excellence (NICE) Clinical guideline [CG191] - Pneumonia in adults: diagnosis and management www.nice.org.uk\/guidance\/cg191 2014"},{"issue":"10","key":"10.1002\/14651858.CD009070.pub2-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002109.pub4","article-title":"Antibiotics for community-acquired pneumonia in adult outpatients","author":"Pakhale","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"24","key":"10.1002\/14651858.CD009070.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007577.pub3","article-title":"Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults","author":"Pugh","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ccm.2004.10.006","article-title":"Antimicrobial treatment of community-acquired pneumonia","volume":"26","author":"Restrepo","year":"2005","journal-title":"Clinics in Chest Medicine"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0116|cit116","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"16","key":"10.1002\/14651858.CD009070.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMp078032","article-title":"The FDA and the case of Ketek","volume":"356","author":"Ross","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/resp.12851","article-title":"Age-related risk factors for bacterial aetiology in community-acquired pneumonia","volume":"21","author":"Sahuquillo-Arce","year":"2016","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Sazawal S Black RE Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials Lancet Infectious Diseases 2003 547 56","DOI":"10.1016\/S1473-3099(03)00737-0"},{"issue":"11","key":"10.1002\/14651858.CD009070.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 7A","key":"10.1002\/14651858.CD009070.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2005.05.010","article-title":"Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting","volume":"118","author":"Segreti","year":"2005","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0122|cit122","doi-asserted-by":"crossref","unstructured":"Simpson SH Marrie TJ Majumdar SR Do guidelines guide pneumonia practice: a systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia Respiratory Care Clinics of North America 2005 1 13","DOI":"10.1016\/j.rcc.2004.10.001"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1179\/joc.1998.10.1.64","article-title":"Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course","volume":"10","author":"Socan","year":"1998","journal-title":"Journal of Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD009070.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/514675","article-title":"High-resolution computed tomography for the diagnosis of community-acquired pneumonia","volume":"27","author":"Syrjala","year":"1998","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD009070.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"e7137","DOI":"10.1371\/journal.pone.0071375","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia","volume":"8","author":"Tichopad","year":"2013","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0127|cit127","first-page":"223.e1","article-title":"Multidisciplinary guidelines for the management of community-acquired pneumonia","volume":"140","author":"Torres","year":"2013","journal-title":"Medicina Clinica"},{"issue":"11","key":"10.1002\/14651858.CD009070.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Troitino AX Porhomayon J El-Solh AA Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis Lung 2013 229 37","DOI":"10.1007\/s00408-013-9462-8"},{"issue":"9","key":"10.1002\/14651858.CD009070.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Vardakas KZ Siempos IL Grammatikos A Athanassa Z Korbila IP Falagas ME Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials CMAJ: Canadian Medical Association Journal 2008 1269 77","DOI":"10.1503\/cmaj.080358"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"j5085","DOI":"10.1136\/bmj.j5085","article-title":"CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials","volume":"359","author":"Welch","year":"2017","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0134|cit134","unstructured":"World Health Organization Health topics - adolescent health www.who.int\/topics\/adolescent_health\/en\/ 2010"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0135|cit135","unstructured":"World Health Organization Antimicrobial resistance: global report on surveillance 2014 www.who.int\/drugresistance\/documents\/surveillancereport\/en\/ 2014"},{"key":"10.1002\/14651858.CD009070.pub2-BIB0136|cit136","unstructured":"Wilde Mathews A FDA panel urges prominent warning label for antibiotic. Wall Street Journal. 19 May 2006 www.wsj.com\/articles\/SB114799677462757266"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0038-1633900","article-title":"Some problems with the investigation of noninferiority in meta-analysis","volume":"43","author":"Witte","year":"2004","journal-title":"Methods of Information in Medicine"},{"issue":"8534","key":"10.1002\/14651858.CD009070.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(87)90430-2","article-title":"Prospective study of the aetiology and outcome of pneumonia in the community","volume":"1","author":"Woodhead","year":"1987","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009070.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jac\/46.1.141","article-title":"Local antibiotic guidelines for adult community-acquired pneumonia (CAP): a survey of UK hospital practice in 1999","volume":"46","author":"Woodhead","year":"2000","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD009070.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","article-title":"Guidelines for the management of adult lower respiratory tract infections - summary","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clinical Microbiology and Infection"},{"issue":"5","key":"10.1002\/14651858.CD009070.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"651-62, 662.e1-","DOI":"10.1016\/j.annemergmed.2007.10.022","article-title":"Evidence-based emergency medicine\/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia","volume":"51","author":"Yu","year":"2008","journal-title":"Annals of Emergency Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009070.pub2-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009070","article-title":"Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients","author":"Rodriguez-Barrientos","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009070.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T18:43:01Z","timestamp":1693852981000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009070.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Acute Respiratory Infections Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":142,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009070.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]}}}